Jacob Moe, DO
Endocrinology, Diabetes & Metabolism · Farmington Hills, MINPI 1043574478
Payments from drug & device makers
Across 322 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$1K
- Lilly USA, LLC$812
- AstraZeneca$342
- AbbVie$275
- Dexcom, Inc.$271
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,651100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 96 | $1,776 |
| Amgen(2 entities) | 47 | $1,054 |
| Lilly USA, LLC | 33 | $812 |
| AstraZeneca | 16 | $342 |
| AbbVie | 13 | $275 |
| Dexcom, Inc. | 14 | $271 |
| Abbott | 12 | $220 |
| Sanofi-aventis U.S. LLC | 10 | $177 |
| Mannkind Corporation | 8 | $157 |
| Insulet Corporation | 7 | $149 |
| Boehringer Ingelheim | 3 | $147 |
| Ascendis Pharma Endocrinology Inc | 1 | $147 |
| Merck | 9 | $128 |
| BETA Bionics, Inc. | 1 | $120 |
| Corcept Therapeutics | 5 | $107 |
| Pfizer | 6 | $99 |
| Amneal Pharmaceuticals LLC | 6 | $89 |
| Antares Pharma, Inc. | 4 | $66 |
| Medtronic(2 entities) | 3 | $54 |
| Alvogen Inc | 2 | $42 |
| Shire North American Group Inc | 3 | $41 |
| Radius Health, Inc. | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Recordati_rare_diseases_inc. | 2 | $35 |
| Amryt Pharma Holdings Ltd | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $25 |
| Companion Medical, Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Valeritas, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Bayer | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Gilead | 1 | $16 |
| IBSA Pharma Inc. | 1 | $14 |
| Lifescan, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$523
- Prolia$410
- iLet Bionic Pancreas$361
- Ozempic$250
- Xultophy 100/3.6$222
- XGEVA$142
- RYBELSUS$125
- FARXIGA$125
- MOUNJARO$122
- JARDIANCE$115
How this compares
$6,663 in reported general payments places this provider in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 177 | $238,516 |
| OzempicSemaglutide | 96 | $173,172 |
| TrulicityDulaglutide | 82 | $155,318 |
| JardianceEmpagliflozin | 54 | $78,366 |
| FarxigaDapagliflozin Propanediol | 35 | $36,695 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $26,697 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $18,614 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $16,907 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $13,425 |
| Novolog FlexpenInsulin Aspart | 26 | $11,215 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $8,130 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 31 | $4,459 |
| SynthroidLevothyroxine Sodium | 40 | $2,725 |
| Levothyroxine Sodium | 177 | $2,453 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 11 | $1,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $812 | $393,834259 claims |
| Novo NordiskOzempic | $1,776 | $173,17296 claims |
| Boehringer IngelheimJardiance | $147 | $78,36654 claims |
| AstraZenecaFarxiga | $342 | $36,69535 claims |
| AbbVieSynthroid | $275 | $2,72540 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $89 | $2,453177 claims |
| PfizerLevoxyl | $99 | $82029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Farmington Hills
- Lowell SchmeltzFarmington Hills$2.3M
- Gary EdelsonFarmington Hills$503K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.